Shares of Eli Lilly (NYSE: LLY) climbed more than 3% as traders reacted to a new FDA approval. The U.S. Food and Drug Administration approved tirzepatide, a diabetes treatment developed by the pharmaceutical company. This approval is expected to boost Eli Lilly's market position in the diabetes care sector.
Tirzepatide is designed to improve glycemic control in adults with type 2 diabetes. The drug activates the body's receptors for metabolic hormones that help regulate blood sugar levels. It can be administered as a once-weekly injection, offering patients a convenient treatment option.
The drug's effectiveness in lowering A1C levels is a major factor in its approval. A phase 3 clinical trial demonstrated that tirzepatide outperformed existing treatment options in reducing A1C. This result is significant as A1C is a key measure of average blood sugar levels.
Tirzepatide has additional benefits beyond diabetes management. Participants in the study who received the drug also experienced substantial weight loss. The average weight loss ranged between 12 and 25 pounds. This has generated interest from doctors and investors in its potential as a treatment for obesity.
Eli Lilly plans to launch the drug, marketed as Mounjaro, in the U.S. in the coming weeks. The company aims to address the significant need for improved diabetes treatment, as over 30 million Americans live with the disease. With effective glycemic control and weight loss benefits, Mounjaro may help many patients better manage their condition.